Imugene Ltd's (ASX:IMU) (OTCMKTS:IUGNF) Leslie Chong speaks to Proactive's Andrew Scott after announcing they've received US Food and Drug Administration (FDA) Investigational New Drug (IND) approval to initiate a phase-1 clinical trial of its checkpoint immunotherapy candidate, PD1-Vaxx in the USA. The approval allows Imugene to initiate patient recruitment and dosing in its phase-1 clinical study in non-small cell lung cancer (NSCLC) patients.
Imugene CEO says FDA IND approval for PD1-Vaxx is 'huge news' for the company
Quick facts: Imugene Ltd
Price: 0.11 AUD
Market Cap: $521.5 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE